Literature DB >> 11948491

Loss of tumor suppressor protein PTEN during renal carcinogenesis.

Walburgis Brenner1, Gloria Färber, Thomas Herget, Hans-Anton Lehr, Jan G Hengstler, Joachim W Thüroff.   

Abstract

The tumor suppressor gene PTEN (phosphatase and tensin homologue deleted from chromosome 10) encodes a dual specific protein and phospholipid phosphatase that affects cell proliferation, apoptosis and migration. In our study, we examined protein expression of PTEN in renal carcinogenesis. PTEN protein levels were examined in 42 clear cell renal cell carcinomas (ccRCC) and oncocytomas as well as in the corresponding normal renal tissue of the same patients using Western blot analysis. Cellular localization was analyzed by immunohistochemistry. PTEN was highly expressed in all investigated normal renal tissue specimens. Immunohistochemical analysis showed an almost exclusive staining of proximal tubulus epithelial cells known to be precursor cells of ccRCC. Within the proximal tubulus cells, PTEN exhibited a membrane predominant immunostaining pattern. In ccRCCs PTEN expression was markedly reduced to an average of less than 10% compared with normal tissue as evidenced by Western blot analysis (p < 0.001). The degree of reduction was similar in highly differentiated (G1) carcinomas and in less differentiated (G2-G4) carcinomas. These observations were reproduced by immunohistochemical studies, which revealed a loss of the characteristic membrane predominant immunostaining pattern in ccRCC. In contrast to the PTEN positive proximal tubulus epithelial cells, the distal tubulus epithelial cells, which are precursor cells of the benign oncocytomas, exhibited only a very weak PTEN expression. Compared with the distal tubulus epithelial cells, no downregulation of PTEN was seen in oncocytomas. We conclude that PTEN expression and PTEN membrane localization are lost during early renal cell carcinogenesis and may therefore be a valuable RCC tumor marker. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948491     DOI: 10.1002/ijc.10303

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

1.  [Kidney tumors].

Authors:  J W Thüroff
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

2.  Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Authors:  Luciana Schultz; Alcides Chaux; Roula Albadine; Jessica Hicks; Jenny J Kim; Angelo M De Marzo; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

3.  Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome.

Authors:  Jessica L Mester; Ming Zhou; Nichole Prescott; Charis Eng
Journal:  Urology       Date:  2012-03-03       Impact factor: 2.649

Review 4.  Perspectives in drug development for metastatic renal cell cancer.

Authors:  Bristi Basu; Tim Eisen
Journal:  Target Oncol       Date:  2010-08-06       Impact factor: 4.493

Review 5.  Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.

Authors:  I Duran; J Lambea; P Maroto; J L González-Larriba; Luis Flores; S Granados-Principal; M Graupera; B Sáez; A Vivancos; O Casanovas
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

Review 6.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

Review 7.  Renal Cell Carcinoma: Molecular Aspects.

Authors:  Aman Kumar; Niti Kumari; Vinny Gupta; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2017-11-13

8.  SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.

Authors:  Guoqiang Li; Weimin Ci; Subhradip Karmakar; Ke Chen; Ruby Dhar; Zhixiang Fan; Zhongqiang Guo; Jing Zhang; Yuwen Ke; Lu Wang; Min Zhuang; Shengdi Hu; Xuesong Li; Liqun Zhou; Xianghong Li; Matthew F Calabrese; Edmond R Watson; Sandip M Prasad; Carrie Rinker-Schaeffer; Scott E Eggener; Thomas Stricker; Yong Tian; Brenda A Schulman; Jiang Liu; Kevin P White
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

9.  Adhesion of renal carcinoma cells to endothelial cells depends on PKCmu.

Authors:  Walburgis Brenner; Silke Beitz; Elke Schneider; Frank Benzing; Ronald E Unger; Frederik C Roos; Joachim W Thüroff; Christian Hampel
Journal:  BMC Cancer       Date:  2010-05-06       Impact factor: 4.430

Review 10.  Angiogenesis and angiogenic inhibitors in renal cell carcinoma.

Authors:  Rishi Sawhney; Fairooz Kabbinavar
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.